GLP-1 Agonists & SGLT2 Inhibitors — GLP-1 agonists and SGLT2 inhibitors: mechanisms and key risks - Pharmacology

SECTION 1

Historical Context & Motivation

For much of the twentieth century, the pharmacological management of type 2 diabetes mellitus (T2DM) relied heavily on insulin, sulfonylureas, and metformin—agents that primarily target insulin secretion or hepatic glucose output. While effective, these therapies carried significant limitations: sulfonylureas risk hypoglycemia and weight gain, and insulin therapy demands careful titration. Researchers recognized that the pathophysiology of T2DM extends far beyond beta-cell failure to include impaired incretin signaling, excessive renal glucose reabsorption, and complex cardiometabolic derangements. This broader understanding catalyzed the search for drug classes that could address these parallel mechanisms.

The discovery that gut-derived hormones potentiate insulin release—termed the incretin effect—opened a new therapeutic axis. Simultaneously, the observation that certain inherited mutations in the renal sodium-glucose cotransporter lead to benign glycosuria without hypoglycemia suggested that blocking renal glucose reabsorption could safely lower blood glucose. These two lines of inquiry ultimately gave rise to GLP-1 receptor agonists and SGLT2 inhibitors, respectively.

1964 • Discovery of the Incretin Effect

Elrick, McIntyre, and colleagues demonstrate that oral glucose provokes a greater insulin response than intravenous glucose at equivalent plasma concentrations, revealing gut-mediated potentiation of insulin secretion.

1987 • Isolation of Exendin-4

John Eng isolates exendin-4 from Gila monster (Heloderma suspectum) venom—a peptide sharing ~53% homology with human GLP-1 yet resistant to DPP-4 degradation, laying the foundation for the first GLP-1 receptor agonist.

2005 • FDA Approval of Exenatide

Exenatide (Byetta) becomes the first commercially available GLP-1 receptor agonist, demonstrating glucose-dependent insulin secretion and meaningful weight loss in clinical trials.

2013 • Launch of SGLT2 Inhibitors

Canagliflozin receives FDA approval, marking the first SGLT2 inhibitor on the market. Dapagliflozin and empagliflozin follow shortly after, establishing a novel insulin-independent approach to glycemic control.

2015–2023 • Cardiovascular and Renal Outcome Trials

Landmark trials—EMPA-REG OUTCOME, LEADER, DAPA-HF, CREDENCE, and SELECT—demonstrate that both drug classes confer cardioprotective and renoprotective benefits that extend well beyond glycemic control, reshaping clinical guidelines worldwide.

The central question these drug classes answer is compelling: Can we lower glucose, protect the heart and kidneys, and promote weight loss—all without significant hypoglycemia? Understanding the mechanisms behind GLP-1 agonists and SGLT2 inhibitors, as well as their key risks, is now essential knowledge for every healthcare professional involved in managing metabolic disease.

SECTION 2

Core Principles & Definitions

Before exploring the detailed pharmacology of each class, it is essential to anchor several foundational concepts that underpin how these agents work, why they differ from older antidiabetic drugs, and why they confer benefits beyond glucose lowering.

The Incretin Effect

Oral glucose stimulates intestinal L-cells to release GLP-1 and GIP, which account for ~50–70% of postprandial insulin secretion. Native GLP-1 has a half-life of only ~2 minutes due to rapid cleavage by dipeptidyl peptidase-4 (DPP-4). GLP-1 receptor agonists are engineered to resist this degradation.

Glucose-Dependent Insulin Secretion

GLP-1 agonists stimulate insulin release only when plasma glucose is elevated. As glucose normalizes, the insulinotropic signal attenuates, which dramatically reduces the risk of hypoglycemia compared to sulfonylureas or exogenous insulin.

Renal Glucose Handling

The kidneys filter approximately 180 g of glucose daily, nearly all of which is reabsorbed in the proximal convoluted tubule via SGLT2 (responsible for ~90%) and SGLT1 (~10%). SGLT2 inhibitors block this transporter, causing therapeutic glycosuria of ~70 g/day.

Insulin-Independent Mechanism

Unlike most antidiabetic drugs, SGLT2 inhibitors do not depend on beta-cell function or insulin sensitivity. Their efficacy is tied to glomerular filtration rate, making them effective even in the setting of progressive beta-cell failure but less effective in advanced CKD for glucose lowering.

Pleiotropic Cardiorenal Effects

Both classes exert cardiovascular and renal benefits that appear partially independent of HbA1c reduction. Proposed mechanisms include natriuresis, reduced preload, anti-inflammatory signaling, improved endothelial function, and favorable shifts in myocardial substrate metabolism.

✦

KEY TAKEAWAY

Think of GLP-1 agonists as a smart thermostat for insulin release—they turn up the signal when glucose is high and dial it back when levels normalize, preventing overcorrection. SGLT2 inhibitors, by contrast, act like a pressure-relief valve on the kidney, allowing excess glucose (and sodium) to escape in the urine, which simultaneously lightens the metabolic and hemodynamic load on the heart and kidneys.

SECTION 3

Visual Explanation — Mechanisms of Action

The left panel illustrates the GLP-1 receptor agonist pathway: binding to the GLP-1 receptor on pancreatic β-cells activates cAMP-mediated signaling, enhancing glucose-dependent insulin secretion while simultaneously suppressing glucagon release, delaying gastric emptying, and reducing appetite through central satiety pathways. The right panel shows how SGLT2 inhibitors block the sodium-glucose cotransporter-2 in the renal proximal tubule, producing glycosuria and natriuresis that lower glucose, blood pressure, and cardiac preload.

The diagram above encapsulates the fundamental difference between these two drug classes. GLP-1 agonists operate primarily through the incretin axis, engaging multiple organ systems—pancreas, gut, and brain—to modulate glucose and appetite. Their cardiovascular benefit is thought to stem largely from anti-atherogenic effects, reducing major adverse cardiovascular events (MACE). SGLT2 inhibitors, by contrast, work through an insulin-independent renal mechanism that produces hemodynamic changes beneficial in heart failure. Notably, both classes share a favorable side-effect profile with minimal hypoglycemia risk and clinically meaningful weight reduction, distinguishing them from older therapies.

SECTION 4

Deep-Dive Mechanisms

GLP-1 Receptor Agonist Signaling Cascade

When a GLP-1 receptor agonist binds the GLP-1 receptor—a G_s-coupled receptor on pancreatic β-cells—it activates adenylyl cyclase, increasing intracellular cyclic adenosine monophosphate (cAMP). Elevated cAMP activates protein kinase A (PKA) and Epac2, which sensitize the exocytotic machinery to intracellular calcium transients generated by glucose metabolism. Because this process requires glucose-derived ATP to close K_ATP channels and depolarize the cell, insulin release remains strictly glucose-dependent. At euglycemic levels, the K_ATP channels remain open, the cell stays hyperpolarized, and insulin secretion is minimal—explaining the remarkably low hypoglycemia risk.

Beyond the pancreas, GLP-1 agonists act on the hypothalamic arcuate nucleus to enhance POMC/CART signaling and suppress NPY/AgRP pathways, reducing appetite and promoting early satiety. In the gastrointestinal tract, these agents slow gastric emptying through vagal-mediated reflexes, blunting postprandial glucose excursions. There is also growing evidence for direct anti-inflammatory and anti-atherogenic effects on vascular endothelium, which may explain the reduction in MACE observed in cardiovascular outcome trials.

SGLT2 Inhibitor Renal and Systemic Effects

Sodium-glucose cotransporter 2 (SGLT2) is a low-affinity, high-capacity transporter located on the luminal membrane of the S1 and S2 segments of the proximal convoluted tubule. It mediates the reabsorption of approximately 90% of filtered glucose (~160–180 g/day) by co-transporting one glucose molecule with one sodium ion. SGLT2 inhibitors selectively and reversibly block this transporter, lowering the renal threshold for glucose (T_mG) from approximately 200 mg/dL to roughly 40–80 mg/dL, resulting in therapeutic glycosuria of approximately 70 g glucose per day.

CALORIC DEFICIT FROM GLYCOSURIA

Daily caloric loss ≈ 70 g glucose × 4 kcal/g = 280 kcal/day

This ~280 kcal/day deficit accounts for the modest weight loss (~2–3 kg) observed with SGLT2 inhibitors. Actual weight loss may be attenuated by compensatory increases in caloric intake.

The co-transport of sodium alongside glucose means that SGLT2 inhibition simultaneously promotes natriuresis. Increased sodium delivery to the macula densa restores tubuloglomerular feedback (TGF), causing afferent arteriolar constriction and a mild, sustained reduction in intraglomerular pressure. This hemodynamic effect is believed to be a central driver of the renoprotection observed in trials like CREDENCE and DAPA-CKD, slowing progression of diabetic kidney disease. Additionally, the mild osmotic diuresis reduces extracellular fluid volume and cardiac preload, which explains the robust benefits in heart failure with reduced and preserved ejection fraction.

⚠

Substrate Shift and Ketogenesis

By promoting urinary glucose loss, SGLT2 inhibitors shift the body's metabolic fuel preference toward fatty acid oxidation and ketogenesis. While mild ketonemia may actually be cardioprotective—ketone bodies like β-hydroxybutyrate are an efficient myocardial fuel—this same mechanism underlies the risk of euglycemic diabetic ketoacidosis (euDKA), a rare but serious adverse effect discussed in later sections.

SECTION 5

Drug Profiles & Classification

GLP-1 Receptor Agonists — Key Agents

Drug (Brand)	Route / Frequency	Half-life	Key Features
Exenatide (Byetta)	SC, twice daily	~2.4 h	First-in-class; derived from exendin-4; short-acting, primarily targets postprandial glucose
Liraglutide (Victoza)	SC, once daily	~13 h	Fatty acid acylation enables albumin binding; LEADER trial showed ↓ CV death
Semaglutide (Ozempic / Rybelsus / Wegovy)	SC weekly or oral daily	~7 days (SC)	Most potent HbA1c and weight reduction; oral formulation available via SNAC co-formulation; approved for obesity (Wegovy)
Dulaglutide (Trulicity)	SC, once weekly	~5 days	IgG4-Fc fusion protein; REWIND trial showed CV benefit even in lower-risk patients
Tirzepatide (Mounjaro / Zepbound)	SC, once weekly	~5 days	Dual GIP/GLP-1 agonist; superior HbA1c and weight reduction vs. semaglutide in SURPASS trials; also approved for obesity

Selected GLP-1 receptor agonists in clinical use

SGLT2 Inhibitors — Key Agents

Drug (Brand)	Selectivity (SGLT2:SGLT1)	Landmark Trial(s)	Notable Indications
Canagliflozin (Invokana)	~250:1	CANVAS, CREDENCE	T2DM, diabetic kidney disease; note: higher amputation signal in CANVAS
Dapagliflozin (Farxiga)	~1200:1	DAPA-HF, DAPA-CKD, DELIVER	T2DM, HFrEF, HFpEF, CKD (with or without diabetes)
Empagliflozin (Jardiance)	~2500:1	EMPA-REG OUTCOME, EMPEROR-Reduced, EMPEROR-Preserved	T2DM, HFrEF, HFpEF; first SGLT2i to show ↓ CV death
Ertugliflozin (Steglatro)	~2000:1	VERTIS CV	T2DM; non-inferior but no superiority for MACE in VERTIS CV

Approved SGLT2 inhibitors with selectivity and trial data

Left: Under normal physiology, SGLT2 reabsorbs virtually all filtered glucose, producing glucose-free urine. Right: When an SGLT2 inhibitor blocks the transporter, the renal threshold for glucose drops, causing approximately 70 g of glucose to be excreted daily alongside increased sodium excretion.

SECTION 6

Worked Example — Clinical Scenario Analysis

Clinical Case: Selecting Therapy for a Patient with T2DM and Heart Failure

1
Step 1 — Identify Clinical Context

A 62-year-old man with T2DM (HbA1c 8.2%), heart failure with reduced ejection fraction (HFrEF, LVEF 35%), eGFR 55 mL/min/1.73 m², and a BMI of 34 kg/m² presents on metformin 1000 mg twice daily. His physician must select an additional antidiabetic agent that addresses glycemic control, cardiovascular risk, renal protection, and weight management.

Key parameters: HbA1c 8.2%, HFrEF (LVEF 35%), eGFR 55, BMI 34
2
Step 2 — Evaluate Guideline Recommendations

Per ADA/EASD consensus, patients with established heart failure should receive an SGLT2 inhibitor with proven HF benefit (dapagliflozin or empagliflozin), regardless of HbA1c target. If additional glycemic control or weight loss is needed, a GLP-1 receptor agonist with proven cardiovascular benefit can be added. In this case, the presence of HFrEF makes SGLT2 inhibitors the first priority.

Priority: SGLT2 inhibitor (empagliflozin or dapagliflozin)
3
Step 3 — Assess Contraindications and Precautions

The patient's eGFR of 55 mL/min/1.73 m² is above the threshold for initiation of all approved SGLT2 inhibitors (current guidelines allow initiation down to eGFR ≥ 20 mL/min/1.73 m² for cardio-renal indications). He has no history of recurrent urinary tract infections or genital mycotic infections. He does not use insulin or sulfonylureas, so the risk of hypoglycemia is minimal. There is no history of DKA, type 1 diabetes, or conditions predisposing to ketoacidosis.

No contraindications identified; proceed with SGLT2 inhibitor.
4
Step 4 — Estimate Expected Outcomes

Based on clinical trial data, adding empagliflozin 10 mg to this patient's regimen can be expected to produce: an HbA1c reduction of approximately 0.5–0.8%, weight loss of ~2–3 kg, systolic blood pressure reduction of ~3–5 mmHg, and—most importantly—a relative risk reduction of approximately 35% for HF hospitalization (per EMPEROR-Reduced). The expected renal glucose excretion of ~70 g/day equates to ~280 kcal/day of caloric loss. The eGFR may dip by 2–5 mL/min acutely due to TGF-mediated afferent arteriolar constriction, but this hemodynamic change is renoprotective long-term.

Expected: HbA1c ↓ 0.5–0.8%, weight ↓ 2–3 kg, ~35% ↓ HF hospitalization
5
Step 5 — Determine If Additional Therapy Is Needed

If HbA1c remains above target (e.g., > 7.0%) after 3 months on metformin plus empagliflozin, the addition of a GLP-1 receptor agonist such as semaglutide would be appropriate. Semaglutide would provide additional HbA1c reduction (~1.0–1.5%), significant weight loss (~5–10 kg), and further cardiovascular benefit through anti-atherogenic mechanisms (MACE reduction). The combination of SGLT2 inhibitor + GLP-1 agonist is now considered a preferred dual add-on for patients with T2DM and high cardiorenal risk.

Final plan: Metformin + Empagliflozin ± Semaglutide (if HbA1c remains above target)

SECTION 7

Key Risks & Adverse Effects

While both drug classes carry favorable safety profiles relative to older antidiabetic agents, each has a distinct adverse-effect spectrum that clinicians must understand to counsel patients effectively and monitor appropriately. The following table organizes the key risks by class and severity.

Adverse Effect	GLP-1 Agonists	SGLT2 Inhibitors
GI effects (nausea, vomiting, diarrhea)	Very common (20–50%); dose-dependent; usually improves with slow titration over weeks. Main reason for discontinuation.	Uncommon; not a class effect.
Genital mycotic infections	Not associated.	Common (5–10%); glycosuria creates a glucose-rich environment favoring Candida growth, especially in women. Usually responsive to topical antifungals.
Urinary tract infections	Not associated.	Modest increase in risk; glycosuria may promote bacterial growth. Rare but serious: Fournier's gangrene (necrotizing fasciitis of the perineum)—an FDA boxed warning consideration.
Euglycemic DKA	Not associated.	Rare but dangerous. Patients may present with normal or mildly elevated glucose but significant ketonemia/acidosis. Risk factors: surgery, fasting, reduced carbohydrate intake, insulin dose reduction, type 1 diabetes (off-label use).
Pancreatitis	Small signal in post-marketing data; causality debated. Contraindicated in patients with history of pancreatitis.	Not associated.
Medullary thyroid carcinoma (MTC)	Boxed warning (rodent C-cell tumors at supratherapeutic doses). Contraindicated in personal/family history of MTC or MEN2 syndrome. Clinical relevance in humans uncertain.	Not associated.
Volume depletion / hypotension	Not a primary risk.	Risk due to osmotic diuresis and natriuresis; caution in elderly patients, those on loop diuretics, or those with low systolic BP.
Hypoglycemia	Low risk as monotherapy (glucose-dependent mechanism). Risk increases when combined with insulin or sulfonylureas.	Low risk as monotherapy (insulin-independent mechanism). Risk increases when combined with insulin or sulfonylureas.
Lower limb amputation	Not associated.	Signal observed with canagliflozin in CANVAS (HR 1.97); not confirmed with other SGLT2 inhibitors. FDA warning issued and later revised.

Comparative adverse-effect profiles of GLP-1 receptor agonists and SGLT2 inhibitors

💊

CLINICAL PEARL

A useful mnemonic for SGLT2 inhibitor risks is "SGLT2 = Sugar Goes Leaving Through 2 kidneys"—remember that glucose in the urine invites infections (mycotic and bacterial), while losing glucose shifts metabolism toward ketones (euDKA risk), and losing sodium/water drops blood pressure (volume depletion). For GLP-1 agonists, think "GI first"—nausea is the most common side effect and the main barrier to compliance. Slow dose titration is the key to tolerability.

SECTION 8

Connection to Advanced & Emerging Therapeutics

The success of GLP-1 agonists and SGLT2 inhibitors has catalyzed a wave of next-generation agents and novel applications. Understanding how these established classes connect to emerging therapeutics provides important clinical context and prepares learners for the evolving pharmacological landscape.

Current Class / Agent	Emerging Extension	Key Advance
GLP-1 mono-agonists (semaglutide)	Dual GIP/GLP-1 agonists (tirzepatide)	Combining incretin signals yields superior HbA1c and weight reduction; ~22% body weight loss with highest dose in SURMOUNT-1
Dual GIP/GLP-1 agonists	Triple agonists (GLP-1/GIP/glucagon; e.g., retatrutide)	Adding glucagon receptor agonism may enhance energy expenditure and hepatic fat reduction; phase 2 trials show ~24% weight loss
SGLT2 inhibitors for T2DM	SGLT2i for HFpEF and CKD (non-diabetic)	DELIVER and DAPA-CKD demonstrated benefits irrespective of diabetes status, expanding indications beyond T2DM
GLP-1 agonists for T2DM	GLP-1 agonists for obesity, MASH, CKD, and CVD prevention	SELECT trial showed semaglutide ↓ MACE in obese non-diabetic patients; FLOW trial showed renal benefits; MASH trials ongoing
Oral semaglutide (SNAC co-formulation)	Oral non-peptide GLP-1 agonists (orforglipron, danuglipron)	Small-molecule GLP-1 agonists that do not require specialized absorption enhancers, potentially improving bioavailability and reducing cost

Current agents and their emerging therapeutic extensions

The trajectory of these drug classes illustrates a broader theme in modern pharmacology: agents initially developed for a single indication (hyperglycemia) are progressively redefining therapy across cardiology, nephrology, hepatology, and obesity medicine. As multi-agonist peptides and oral non-peptide formulations enter clinical practice, the pharmacological repertoire for cardiometabolic disease will continue to expand dramatically. Students should anticipate that guidelines will increasingly emphasize organ-protective therapy selection rather than glycemic targets alone.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Explain why GLP-1 receptor agonists carry a significantly lower risk of hypoglycemia compared to sulfonylureas, even though both classes enhance insulin secretion from pancreatic β-cells.

Show answer

GLP-1 receptor agonists stimulate insulin secretion through a glucose-dependent mechanism: their insulinotropic effect requires elevated intracellular glucose metabolism to close K_ATP channels and depolarize the β-cell. At normal or low glucose levels, K_ATP channels remain open and the cell stays hyperpolarized, so the cAMP signal from GLP-1 receptor activation cannot trigger exocytosis. Sulfonylureas, by contrast, directly close K_ATP channels regardless of ambient glucose concentration, causing insulin release even during euglycemia or hypoglycemia. This fundamental difference in coupling insulin secretion to glucose levels explains the markedly lower hypoglycemia risk with GLP-1 agonists.

Question 2: BASIC CALCULATION

A patient's kidneys filter 180 g of glucose per day. While on empagliflozin, renal glucose reabsorption decreases to approximately 110 g/day. Calculate the daily caloric loss from glycosuria and estimate the weekly caloric deficit.

Show answer

Glucose excreted per day = 180 g − 110 g = 70 g/day. Since glucose provides approximately 4 kcal per gram, the daily caloric loss is 70 × 4 = 280 kcal/day. Over one week, this amounts to 280 × 7 = 1,960 kcal/week. In practice, actual weight loss may be less than predicted by this deficit because compensatory increases in caloric intake and metabolic adaptation partially offset the urinary glucose losses.

Question 3: INTERMEDIATE

A 58-year-old woman with T2DM is started on dapagliflozin. Three weeks later, she presents to the emergency department with nausea, vomiting, and abdominal pain. Her blood glucose is 165 mg/dL, but arterial blood gas reveals pH 7.18 and serum β-hydroxybutyrate is markedly elevated. What is the most likely diagnosis, and what factors may have precipitated this event?

Show answer

The most likely diagnosis is euglycemic diabetic ketoacidosis (euDKA), a known adverse effect of SGLT2 inhibitors. The blood glucose of 165 mg/dL is only mildly elevated—far below the typical threshold of > 250 mg/dL seen in classic DKA—which can delay recognition. SGLT2 inhibitors promote ketogenesis by shifting fuel metabolism from glucose to fatty acids. Precipitating factors include recent reduction in insulin dose, carbohydrate-restricted diets, prolonged fasting, dehydration, acute illness, excessive alcohol intake, or surgical stress. Management involves insulin infusion, intravenous dextrose-containing fluids (since glucose is near-normal), and electrolyte replacement, along with discontinuation of the SGLT2 inhibitor.

Question 4: APPLIED

A physician is choosing between adding semaglutide or empagliflozin to metformin for a 65-year-old man with T2DM (HbA1c 8.5%), BMI 38, established atherosclerotic cardiovascular disease (prior MI), and an eGFR of 45 mL/min/1.73 m². Using current ADA/EASD guidelines and clinical trial evidence, construct a brief argument for each option and state which agent—or combination—would be most appropriate and why.

Show answer

Both classes are indicated. Semaglutide would offer superior HbA1c reduction (~1.0–1.5%), substantial weight loss (~10–15% with higher doses), and proven MACE reduction in the SUSTAIN-6 and SELECT trials—highly relevant given this patient's prior MI and obesity. Empagliflozin would provide modest HbA1c reduction (~0.5–0.7% at eGFR 45), renoprotection via TGF restoration (slowing eGFR decline), HF hospitalization reduction, and mild weight loss. Given the patient's established ASCVD, both agents are guideline-recommended. The ideal strategy for this high-risk patient would be combination therapy with both semaglutide and empagliflozin, as the mechanisms are complementary (anti-atherogenic + hemodynamic/renoprotective) and the ADA specifically endorses dual therapy with these classes for patients with high cardiorenal risk.

Question 5: CRITICAL THINKING

SGLT2 inhibitors demonstrate renoprotection in clinical trials, yet their glucose-lowering efficacy diminishes as eGFR declines below 45 mL/min/1.73 m². If glycemic efficacy depends on glomerular filtration, how can the renoprotective benefit persist at low eGFR levels? Discuss the proposed mechanism and its implications for prescribing.

Show answer

This apparent paradox is resolved by recognizing that the renoprotective effect of SGLT2 inhibitors is largely independent of glycosuria. The primary renoprotective mechanism is the restoration of tubuloglomerular feedback (TGF). By blocking SGLT2, more sodium reaches the macula densa, triggering afferent arteriolar vasoconstriction that reduces intraglomerular pressure—a key driver of progressive nephropathy. This hemodynamic effect operates regardless of whether substantial glucose is filtered and excreted. In diabetic nephropathy, the proximal tubule maladaptively upregulates SGLT2, causing excessive sodium and glucose reabsorption and blunting TGF, which leads to afferent vasodilation and glomerular hyperfiltration. SGLT2 inhibitors reverse this pathological state. Additional mechanisms include reduced tubular workload (less reabsorptive energy expenditure), anti-inflammatory effects, and reduced albuminuria. Clinically, this means SGLT2 inhibitors should be continued even as eGFR falls below 45, down to eGFR 20 mL/min/1.73 m² in current labeling, for their cardiorenal benefits despite diminishing glycemic efficacy.

SUMMARY

Lesson Summary

Summary

GLP-1 receptor agonists mimic the endogenous incretin hormone GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon release, delay gastric emptying, and reduce appetite through central satiety pathways. These multi-organ effects produce robust HbA1c reduction and significant weight loss while carrying a low risk of hypoglycemia. Key risks include GI side effects (nausea, vomiting), a boxed warning for medullary thyroid carcinoma risk (from rodent data), and a possible pancreatitis signal. Cardiovascular outcome trials demonstrate MACE reduction, particularly through anti-atherogenic mechanisms.

SGLT2 inhibitors block the sodium-glucose cotransporter-2 in the renal proximal tubule, producing therapeutic glycosuria (~70 g/day) and natriuresis through an insulin-independent mechanism. The resulting hemodynamic changes—reduced preload, restored tubuloglomerular feedback, and lower intraglomerular pressure—confer striking heart failure and renal protective benefits that extend beyond diabetes. Key risks include genital mycotic infections, euglycemic DKA, volume depletion, and rare genitourinary infections. Together, these two drug classes represent the most important therapeutic advance in cardiometabolic pharmacology since metformin, with expanding indications across obesity, heart failure, and chronic kidney disease.